12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Company News  |  Deals

Genmab, J&J deal

Genmab granted Johnson & Johnson's Janssen Biotech Inc. unit exclusive worldwide rights to develop and commercialize cancer product daratumumab ( HuMax-CD38). The human mAb against CD38 is in Phase I/II testing for...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >